中国细胞与基因治疗联盟成立

Group 1 - The China Cell and Gene Therapy Conference (CSGCT) was held, co-hosted by the Zhongguancun Science City Management Committee and the CSGCT Alliance, marking the establishment of the CSGCT Board [1][2] - Beijing has ranked first in the number of approved medical device products in the past three years and third in the approval of innovative Class 1 drugs, with the pharmaceutical and health industry expected to reach a scale of 1.06 trillion yuan in 2024, representing an 8.7% year-on-year growth [1] - Haidian District has leveraged its educational and clinical resources, including 37 higher education institutions and 57 hospitals, to create a "talent highland" for innovation in cell and gene therapy (CGT) [1] Group 2 - The "Blue Book on the Development and Regulatory Policy of China's Cell and Gene Therapy Industry" was released, providing authoritative reference for industry and regulatory dialogue, aimed at advancing four core technology areas: CGT, multi-omics and precision medicine, brain-computer interfaces, and AI healthcare [2] - The newly established CSGCT Alliance will focus on comprehensive planning across various aspects such as policy support, academic research, clinical trials, industry implementation, international cooperation, talent cultivation, and public education to address common challenges in China's CGT industry [2]